Market Share, Licensing, and M&A: Three's Company
Executive Summary
Achieving 10% global market share--Richard Sykes' stated rationale for pursuing another merger for Glaxo--won't accomplish what he wants: sustainable profitability. In the first place, pharmaceutical market share is important largely within categories; in the second, M&A works against achieving significant category share. Not only are antitrust authorities likely to force divestitures within categories; but M&A disrupts in-licensing, so far the only proven supplement to internal R&D for creating major players within categories.
You may also be interested in...
Thermo Fisher Scientific, Hillrom To Acquire Diagnostics Companies To Bolster Portfolios
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Cosmetic And Personal Care Trademark Review 19 January, 2021
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
CMS Extends National Medicare Coverage For Transcatheter Mitral Valve Repair
Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.
Need a specific report? 1000+ reports available
Buy Reports